[Myelopeptides: isolation and structure].

L A Fonina; S A Gur'ianov; M A Efremov; O V Smirnova

Home/Archive/PubMed

PubMed · 9702349

[Myelopeptides: isolation and structure].

L A Fonina·S A Gur'ianov·M A Efremov·O V Smirnova

View original source ↗Export metadata ↓

Abstract

A new method was developed for the isolation of biologically active peptides present in small quantities in supernatants of bone marrow cell cultures. Four new peptides, which exhibited immunostimulating and differentiating activities, were isolated from the supernatant using solid phase extraction and reversed-phase HPLC. For these peptides, the following primary structures were elucidated: Leu-Val-Cys-Tyr-Pro-Gln, Phe-Arg-Pro-Arg-Ile-Met-Thr-Pro, Val-Val-Tyr-Pro-Asp, and Val-Asp-Pro-Pro.

Explore related subjects

Adjuvants, Immunologic Amino Acids Animals Antibody-Producing Cells Bone Marrow Cells Cell Differentiation Cells, Cultured Chemical Fractionation Chromatography, High Pressure Liquid HL-60 Cells Humans Lymph Nodes Mice Oligopeptides Swine English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

L A Fonina, S A Gur'ianov, M A Efremov, O V Smirnova. 1998. [Myelopeptides: isolation and structure].. https://pubmed.ncbi.nlm.nih.gov/9702349/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Application of standardized mistletoe extracts augment immune response and down regulates metastatic organ colonization in murine models.

The immunomodulatory and antimetastatic activity of standardized aqueous mistletoe extracts from plants grown on fir trees (ME-A) and pine trees (ME-P) were evaluated in BALB/c-mice. Regular subcutaneous (s.c.) and intraperitoneal (i.p.) applications (three times per week for 14 consecutive days; 5 and 50 microg per injection and mouse) upregulated thymus weight and peripheral blood leukocyte counts in tumor bearing mice. To check the influence of ME-A and ME-P treatment on growth of experimental metastases, RAW 117 H 10 lymphosarcoma cells and L-1 sarcoma cells were intravenously inoculated into BALB/c-mice to establish liver and lung colonization. ME-A and ME-P were regularly administered starting 24 h after tumor cell challenge. Organ colonization was investigated on day 14 after tumor cell inoculation and demonstrated statistically significant (P<0.05) reductions of experimental liver and lung metastases for ME-A and ME-P treated mice.

Adjuvants, Immunologic↗

PubMed2001

Features of the antibody response attributable to plasmid backbone adjuvanticity after DNA immunization.

DNA vaccination induces antigen-specific immune responses with characteristics distinct from other vaccination modes. In the present study, the contribution of the plasmid backbone adjuvant effect to the quality of the DNA-raised antibody response was investigated. For this purpose, three intradermal primings were compared in mice using: (1) the recombinant Schistosoma haematobium glutathione S-transferase antigen (rSh28GST): (2) rSh28GST supplemented with a non-coding plasmid; and (3) a Sh28GST-encoding plasmid. In contrast to immunization with the protein, DNA immunization elicited a very stable antibody (Ab) response over a prolonged period of time. This feature was attributed to the plasmid backbone, because co-administration of the non-coding plasmid with rSh28GST allowed the maintenance of the specific Ab response. A strong anamnestic Ab response was induced after intradermal boost with rSh28GST only in the mice primed with pMSh. This indicated that the selective ability of DNA vaccination to induce memory humoral response was independent of the plasmid backbone. In contrast the plasmid backbone was found to strongly participate in the preferential IgG2a Ab production observed. These results suggest that, following DNA immunization, the Th1-biased profile and the maintenance of the long-lived Ab response could be attributed to an adjuvant effect of the plasmid backbone during priming, whereas the strength of B-cell memory was independent of this effect.

Adjuvants, Immunologic↗

PubMed2001

Towards the rational design of Th1 adjuvants.

Finding adjuvants in order to enhance immune responses against target immunogens has been a major and recurrent issue for the vaccine industry. It is yet to be solved, most particularly in the context of a growing interest in designing new types of vaccines capable of eliciting Th1 immune responses. A review of synthetic adjuvants which have been (or are being) tested in clinical studies is presented. Importantly, recent advances in our understanding of the physiology of immune responses offer new avenues to design and test candidate adjuvants, based on either synthetic or natural molecules, with the aim to mimic and recapitulate pro-inflammatory signals initiating both innate and adaptative immune effector mechanisms. Thus, adjuvants of the future might be a mixture of molecules selected singularly for a capacity to attract, target or activate professional antigen presenting cells. Used as a combination, such molecules should facilitate antigen presentation by professional APCs and lead to a potent induction of T cell-mediated effector and immune memory mechanisms.

Adjuvants, Immunologic↗